Strategic Partnerships OnDosis actively pursues collaborations with biotech and pharma companies (Revio Therapeutics, Diamond Therapeutics, Camallergy, Emplicure) to expand its dosage management platform across diverse therapeutic areas, signaling opportunities for co-development and integration of its dosage technology with external drug programs.

Personalized Dosing Growth The Dosage Manager targets individualized oral dosing with pellets, granules, mini tablets, or powders, addressing significant unmet needs in ADHD, food allergies, pain, and immunosuppression—areas ripe for partnerships with sponsors seeking precision medicine capabilities.

Drug-Device Collaboration Recent and ongoing announcements emphasize drug-device combination product development, presenting a sales angle for pharma/device integrators looking to optimize dosing accuracy, patient adherence, and dose consistency at scale.

Awarded UX & Innovation Recognition for UX design and product innovation suggests strong market readiness and customer-centric solutions, which can be leveraged in pitches to stakeholders prioritizing usability, patient experience, and regulatory-friendly design.

Global Growth Potential Founded as a spin-out from AstraZeneca with international collaborations and a global partner network, OnDosis presents a scalable platform suitable for multinational trials and access to diverse patient populations, appealing to global licensees and co-development partners.